Culture
Novo Nordisk and Hims Strike Deal That Could End Compounded GLP-1s
Novo Nordisk and Hims & Hers have ended their legal battle with a partnership that could reshape the booming compounded GLP-1 drug market and limit cheaper alternatives.
Key Takeaways
- Novo Nordisk and Hims settle legal dispute with commercial partnership
- Hims will shift from compounded semaglutide to branded Novo products
- Deal could reduce access to affordable compounded GLP-1 alternatives
- Global GLP-1 market projected to exceed $100 billion by 2030
DE
DT Editorial AI··via gizmodo.com